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ABSTRACT
The complex interplay of the tumour microenvironment (TME) and its role in 
disease progression and response to therapy is poorly understood. The majority of 
studies to date focus on individual components or molecules within the TME and so lack 
the power correlative analysis. Here we have performed a multi-parameter analysis 
of the TME in 62 resectable non-small cell lung cancer (NSCLC) specimens detailing 
number and location of immune infiltrate, assessing markers of cancer-associated 
fibroblasts, caveolin-1 and tenascin-C, and correlating with clinicopathological 
details, as well as markers of disease progression such as epithelial-to-mesenchymal 
transition (EMT). The influence of individual parameters on overall survival was 
determined in univariate and multivariate analysis and the combination of risk factors 
and interplay between components analysed. Low numbers of CD8 T cells, low stromal 
levels of caveolin-1 or high levels of tenascin-C were significant prognostic markers 
of decreased overall survival in both univariate and multivariate analysis. Patients 
with two or more risk factors had dramatically reduced overall survival and those 
with all three a median survival of just 7.5 months. In addition, low levels of tumour 
E-cadherin correlated with reduced immune infiltrate into the tumour nests, possibly 
linking EMT to the avoidance of CD8 T cell control. The multicomponent approach has 
allowed identification of the dominant influences on overall survival, and exploration 
of the interplay between different components of the TME in NSCLC.
INTRODUCTION
The influence of the tumour microenvironment 
(TME) upon non-small cell lung cancer (NSCLC) remains 
poorly defined with conflicting reports in the literature 
surrounding the influence of immune components as 
well as cancer-associated fibroblasts (CAFs) on disease 
progression and outcome. The radical success of the early 
trials of PD1/PD-L1 checkpoint inhibitor immunotherapies 
appears to demonstrate that the TME has a guiding 
influence on NSCLC disease outcome and points the way 
for further exploration of TME-targeted therapies [1].
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The complexity of the TME, comprising fibroblasts, 
endothelial cells, pericytes, immune infiltrate and other 
cells along with their secretions and extracellular matrix, 
make it a challenging system to study and many reports 
focus on one part in isolation, potentially overlooking 
important interactions. The major non-tumour cell type 
found in the NSCLC microenvironment are fibroblasts, 
which surround and penetrate through the tumour in a 
web-like pattern. This produces an architecture common 
to many solid tumours where groups of tumour cells are 
clustered in so called nests (or islets) and separated from 
adjacent nests by a swathe of fibroblasts, often including 
the vasculature. The origin and even definition of CAFs 
remains controversial [2] and indeed CAFs themselves are 
a heterogeneous and dynamic population that exists in co-
development with the tumour [3].
Biomarkers of CAFs are beginning to show 
promise in the prognosis of a number of solid tumours 
but have been most extensively studied in breast cancer. 
Caveolin-1, when expressed by fibroblasts, appears to 
negatively regulate tumour cell growth and the loss of 
expression is strongly correlated with reduced overall 
survival, tamoxifen resistance and metastasis in breast 
cancer [4, 5] and high Gleason score in prostate cancer [6]. 
Cav-1 deficient fibroblasts upregulate glycolytic enzymes 
and secrete energy rich metabolites which can be used 
by the proliferating tumour cell in the so called ‘reverse 
Warburg effect’ [7]. Tenascin-C expression by fibroblasts 
has been associated with disease in a number of cancers 
including bladder, brain and colon but only definitively 
linked with poor prognosis or survival in breast and lung 
[8, 9]. Tenascin-C appears to be involved in the metastatic 
process and is often found at the tumours leading edge 
[10], it plays a role in epithelial-to-mesenchymal transition 
(EMT) [11] and has also been shown to block T cell 
activation [12]. As CAFs are known to modulate a number 
of treatments, CAF markers may aid patient stratification 
and chemotherapy choice and may also provide novel 
targets for future chemotherapeutics.
Immune infiltrate is commonly observed in NSCLC 
and is chiefly composed of T cells and macrophages. 
There have been conflicting reports on the importance 
of the composition and influence of location on disease 
progression. Al-Shibli et al. [13] found a significant 
association between increased stromal and intratumoural 
CD8+ T cells and improved disease-specific survival 
whereas Wakabayashi et al. found an association between 
increased intratumoural CD8+ T cells and shorter overall 
survival [14]. Hiraoka et al. found that concurrent CD4+ 
and CD8+ T cell infiltration is a favourable prognostic 
factor [15]. More recently, Djenidi et al. reported that 
CD8+CD103+ tumour infiltrating T cells are a prognostic 
factor for survival in NSCLC [16] and the success of 
checkpoint immunotherapy trials indicates that T cells can 
play an important role in disease control [1]. T-regulatory 
cells are implicated in the dampening of anti-tumour 
immune responses in a number or tumour types [17] 
have been reported to influence disease progression in 
NSCLC. An increased number of total T-reg cells and a 
higher proportion of total T-reg cells relative to tumour-
infiltrating lymphocytes (TILs) has been associated with 
worse recurrence-free survival [18]. A study by Tao 
et al. also found an association between increased total 
T-reg levels and poor overall and relapse-free survival 
[19]. Approximately one third of the immune infiltrate 
in NSCLC are tumour-associated macrophages (TAMs) 
[20], the majority of which are alternatively activated M2 
macrophages [21]. M2 macrophages are implicated in 
disease progression in a number of tumour indications and 
can both act to supress the anti-tumour immune response 
but also facilitate tumour growth and metastasis.
In order to better understand the influence of 
the TME we sought to profile the major cellular TME 
components namely, fibroblasts, T cells (CD3, CD8 and 
T-reg) and macrophages and relate these to patient survival 
in univariate and multivariate analysis in the context of the 
known clinicopathological data.
RESULTS
Immune infiltrate
A cohort of 62 tumour specimens from patients 
with operable NSCLC (stage 1-3) were analysed for their 
immune infiltrate by immunohistochemical analysis. The 
number of each cell-type and location in tumour nest 
or stroma was determined for total T cell (CD3), CD8 
T cells (CD8), T-reg (FoxP3) and macrophages (CD68) 
and related to survival by Kaplan-Meier analysis (Figure 
1). In line with other reports the samples contained high 
numbers of CD3+ T cells predominantly in the tumour 
stroma; approximately two-thirds of these were CD8+ T 
cells which were evenly distributed between tumour nest 
and stroma. A smaller number of CD68+ macrophages 
and FoxP3+ T–regs were observed with roughly equal 
distributions between tumour nest and stroma. Number 
and distribution of immune cells is shown in Figure 1E. 
Kaplan- Meier survival curves were generated for all 
markers dividing the data between high (above mean) 
and low (below mean) infiltration into either tumour nest, 
tumour stroma or the ratio between the two. The strongest 
trends were observed by examining the tumour nest to 
stromal ratios (TN/STR) where those with higher TN/STR 
ratios of CD8, CD68 or FoxP3 had higher overall survival 
(Figure 1F-1H); however, this only reached significance 
for CD8+ T cells (p=0.041 Mantel-Cox Log-rank test, 
p=0.0294 Gehan-Breslow Wilcoxon test).
Cancer- associated fibroblasts
The cohort was examined for two CAF-associated 
proteins with putative prognostic significance: tenascin-C, 
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Figure 1: Number, Localisation and Influence of Immune Infiltrate on Overall Survival in NSCLC. Serial sections of 
FFPE NSCLC tissue (n = 62) were immunohistochemically stained for CD3, CD8, CD68 and FoxP3. Cells were enumerated and location 
categorised as tumour nest (TN), stromal (STR) and the resultant ratio (TN/STR). Example images of staining for (A), CD3; (B), CD8; (C), 
CD68; (D), FoxP3. (E), mean number of tumour-associated cells in each location; error bars represent standard errors of the mean. (F, G, 
H) Kaplan-Meier plots of overall survival of patients divided by low and high (below or above the mean) TN/STR ratio of (F), CD8 cells, 
(G), CD68+ Macrophages and (H), FoxP3+ T-regulatory cells. Significance <0.05 as measured by Log-rank (Mantel-Cox) test are shown.
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which has been shown to be up-regulated in a number 
cancers, and caveolin-1, the loss of which is a strong 
predictor of overall survival in breast cancer and is 
a promising marker in NSCLC [5, 8, 22]. Degree of 
immunohistochemical staining in the stromal cells only 
was graded 0-3 (0 = absence of stain, 1-3 low to high 
staining) and survival of groupings analysed by Kaplan-
Meier plots (Figure 2). Decreased Cav-1 staining in 
stromal fibroblasts was significantly associated with 
decreased overall survival both as a trend (Log-rank test 
for trend p=0.0153) or when comparing low (0-1 score) 
to high (2-3 score) (Log-rank test p=0.0222) in NSCLC. 
Overall survival was significantly reduced in patients with 
increased tenascin-C (Log-rank test for trend p=0.087) 
and there was a marked difference in survival between 
patients with the highest amount of tenascin-C (3 score) 
and those with other scores (0-2) or when low staining 
(0-2) was compared to those with high staining (Log rank 
test p=0.0025). While overall there was a modest trend 
to inverse relationship between Tn-C and Cav-1 levels no 
significant relationship existed (Supplementary Figure 1) 
suggesting these are two distinct biological processes.
Epithelial-to-mesenchymal transition
In order to look for evidence of EMT in the NSCLC 
specimens we quantified E-cadherin levels in the tumour 
cells by H-Score analysis and also scored them for 
expression of the mesenchymal marker vimentin. Figure 
3 shows that low E-cadherin (below mean H-Score: 55% 
of patients) was predictive for worse overall survival 
(Log-rank test p=0.0421, Gehan-Breslow-Wilcoxon test 
p=0.0182) whereas the presence of any vimentin staining 
in any of the tumour cells was not predictive on its own or 
in combination with E-cadherin levels.
It has been recently demonstrated that CD8 T cell 
expression of CD103 is required for retention in tumour 
nests and it is these cells that possess tumour lytic 
ability [16]. As the receptor for CD103 is E-cadherin 
we investigated if lymphocyte infiltrate into the tumour 
nest correlated with E-cadherin expression (Figure 4A). 
E-cadherin levels showed a correlation with high CD8 
TN/STR (rank Spearman p=0.0435) and from this it 
was noted that those cells with low levels of E-cadherin 
had significantly lower numbers of CD8, FoxP3, and 
CD68 cells in the tumour nest but not in the stroma 
Figure 2: Predictive Value CAF Markers in NSCLC. Serial sections of FFPE NSCLC tissue (n = 62) were immunohistochemically 
stained for caveolin-1 (Cav-1) or tenascin-C (Tn-C). Stromal-associated staining was categorised as absent (0) or low-high (1-3) and 
compared to overall survival in Kaplan-Meier survival analysis. (A) Example images of Cav-1 scoring 0-3 (left to right). (B) Example 
images of Tn-C scoring 0-3 (left to right). (C) Survival by level of Cav-1 (0-3 score). (D) Survival by level of Tn-C (0-3 score). (E) Survival 
by level of Cav-1 grouped as low (0-1 score) or high (1-2 score). (F) Survival by level of Tn-C grouped as low (0-2 score) or high (3 score). 
* = significance P <0.05 as measured by Log-rank (Mantel-Cox) between groups and trend= significance of Log-rank test for trend.
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(Supplementary Figure 2) and hence lower TN/STR ratios 
(Figure 4B–4D).
Multivariate analysis and combinatorial risk
While the univariate Kaplan-Meier and Log-rank 
tests had identified low CD8 TN/STR, high Tn-C, low 
Cav-1 and low E-cad as predictors of worse overall 
survival, it was also important to take into account 
the variation in clinical features to determine whether 
they are truly independent predictors of outcome. A 
multivariate analysis (Cox Regression) was performed 
including covariates age, gender, stage of disease and 
disease sub-type. Results of multivariate analysis for 
our investigational markers are shown in Table 1, where 
it can be seen that CD8 numbers (total, tumour nest or 
stromal number) was a significant predictor of survival 
with small hazard ratios; however, high CD8 TN/STR 
ratio was a significant predictor of better overall survival 
(p=0.037) with hazard ratio of 0.645 (95%CI 0.427-
0.974). Both CAF markers were predictive of outcome 
with high levels of Tn-C predictive of worse overall 
survival (p=0.005, HR 2.309) and high levels of Cav-
1 predictive of increased survival (p=0.038, HR 0.635). 
Although included in the analysis age, gender, stage 
of disease and disease sub-type were not independent 
predictors of overall survival in this early stage disease 
cohort.
Figure 3: Loss of Epithelial Marker E-Cadherin Correlates with Worse Overall Survival. Serial sections of FFPE NSCLC 
tissues (n = 41) were immunohistochemically stained for E-cadherin or vimentin. (A) Example images of week, moderate and intense 
E-Cadherin staining (left to right). (B) Matched image analysis (to A) produced by Image Scope Positive Pixel Algorithm with pixels 
coloured as weak (yellow), moderate (orange) or intense (red), extracted values were used to calculate a mean H-Score for each patient. 
(C) Patient survival based on E-Cadherin H-Score grouped as low or high (below or above) the mean H-Score. (D) Presence of vimentin 
staining in any of the tumour nests was categorised as positive, and total absence as negative. * = significance P <0.05 as measured by 
Log-rank (Mantel-Cox) between groups.
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We determined the total number of the three 
independent risk factors (Tn-C high, Cav-1 low and CD8 
TN/STR low) that each patient had and plotted this, sum 
of total risk factor against overall survival (Figure 4). 
Total risk factor score was highly predictive of worse 
overall survival as a trend (p<0001) and when comparing 
0 risk factors to 2 (p=0.0148) or 3 risk factors present 
(p<0.0001). In a multivariate analysis with age, gender, 
stage of disease and disease sub-type as covariates the 
total risk factor score was a significant predictor of worse 
overall survival p<0.0001, HR 3.207 (95%CI 1.907-5.392) 
(Table 1).
DISCUSSION
Using a multi-parameter approach to profile 
components of the TME we have been able to identify low 
CD8 number and absence of infiltration into the tumour 
nests as well as the over-production of Tn-C or reduced 
production of Cav-1 by CAFs as significant predictors 
of shortened overall survival in NSCLC. Uniquely by 
measuring all the parameters together we were able to 
determine that low levels of tumour E-cadherin, which 
appeared predictive of worse overall survival in univariate 
but not multivariate analysis, was a confounder of immune 
infiltration: presence of E-cadherin at moderate or high 
level was critical for the presence of CD8+ T cell, FoxP3+ 
T-regulatory cells and CD68+ macrophages in the tumour 
nests. While we only analysed two indicative markers here 
(E-cadherin and vimentin) any shift to a mesenchymal 
phenotype caused by EMT would cause loss of E-Cadherin 
and may directly inhibit the CD8+ cytotoxic T cell control 
of cancer. The value of the multi-parameter approach was 
demonstrated by the strong predictive value of reduced 
overall survival for patients that had more than one of the 
three risk factors (low CD8, high Tn-C or low Cav-1), 
Figure 4: Immune Infiltration to the Tumour Nests Correlates with Low E-Cadherin Level. (A) Correlation of E-cadherin 
H-score and CD8 tumour nest/stromal ratio. Significance of Spearman’s non-parametric correlation is shown. (B, C, D) TN/STR ratio of 
immune infiltrate in tumours with low E-cadherin (low H-score shown as shaded area in figure A), compared with those with moderate or 
high E-cadherin for: (B) CD8 T cells; (C) CD68+ macrophages or (D) FoxP3+ T-regulatory cells. Significance of Mann-Whitney unpaired 
non-parametric T- test are shown.
AQ:
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with those with all three risk factors present having a 
median survival of just 7.5 months.
Whilst highly predictive of survival in breast cancer, 
low stromal Cav-1 has only recently been shown to be 
of prognostic significance in NSCLC. In a phase II trial 
of nab-paclitaxel and carboplatin in advance squamous 
NSCLC high stromal Cav-1 correlated with improved 
response rate and increased survival [22]. The analysis is 
complicated in NSCLC by tumour cell upregulated Cav-
1 being reported to correlate with poorer survival and 
resistance to therapy [23, 24]. Our study for the first time 
demonstrates across the pathological subtypes that low 
stromal Cav-1 is associated with worse overall survival 
in operable NSCLC patients. Stromal Cav-1 expression in 
breast and ovarian cancer is driven in concert with tumour 
cell oncogene expression with the resulting oxidative stress 
causing a switch from normal to CAF-like phenotype. 
The activated fibroblasts are thought to produce energy 
rich metabolites that help support the growing tumour via 
the reverse Warburg effect [25]. This metabolic coupling 
between the TME and tumour cells represents an as yet 
untapped target for novel chemotherapeutics which are 
desperately needed for the treatment of NSCLC.
Tenascin-C, a component of the extracellular 
matrix, is rarely seen in adult tissue other than in the 
bone marrow or lymphoid tissue or in cases of wound 
healing and solid tumours. While there is evidence in a 
number of tumour indications that larger isoforms are 
more predominantly expressed in tumour stroma there 
are few definitive reports correlating stromal Tn-C with 
disease progression or survival [9]. Tn-C expression was 
predictive of worse overall survival in a study of women 
with node negative breast cancer [26] and, in NSCLC, 
increased Tn-C has been shown to correlate with disease 
recurrence and inhibition of the effector function of TILs 
[12]. Here, in a cohort of operable NSCLC patients we 
see an association of Tn-C and overall survival in both 
univariate and multivariate analysis. Tn-C is expressed 
in primary and secondary lymphoid organs and has been 
shown to interact with and modulate T cell function and 
hence we looked for an association between immune 
cell number and localisation with the level of Tn-C, but 
none was found (Spearman’s correlation P>0.05 for all 
combinations). Given Tn-C expression is usually localised 
to the tumour stroma and has been shown to supress TILs 
from NSCLC, effector T cells that localise to the tumour 
stroma may be inactivated by association with Tn-C and 
in part may explain why T cell localisation appears to be 
important in disease progression.
In this study we focussed on two proteins 
differentially expressed in cancer associated fibroblasts 
of other tumour indications but which have only very 
recently begun to be investigated in NSCLC. The results 
presented here indicate that a systematic investigation 
into role of cancer associated fibroblasts in the disease 
progression of NSCLC is warranted and may yield useful 
targets for future therapy.
Cancer is often referred to as the wound that 
never heals because of the ever-present inflammation 
and similarities to the wound healing process [27]. The 
progression to a more aggressive and invasive phenotype 
including that of EMT has more recently been linked 
Figure 5: Presence of Multiple TME Risk Factors Strongly Predicts for Poorer Overall Survival. The number of risk 
factors (low CD8 TN/STR, high Tn-C and low Cav-1) present in NSCLC samples from each patient was calculated and analysed by in 
Kaplan-Meier survival analysis. Significance <0.05 as measured by Log-rank (Mantel-Cox) between groups is shown. Trend= level of 
significance of Log-rank test for trend.
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with the inflammatory process at cellular and molecular 
levels [28]. Inflammatory cells such as TAMs are 
recruited to the tumour stromal interface and along with 
CAFs secrete cytokines including TNF-α and TGF-β to 
control the inflammatory response and to activate wound 
healing programmes. This signalling and the secretion 
of metalloproteinases by CAFs causes the activation 
of NF-κB in tumours leading to the activation of Snail, 
TWIST and Zeb and ultimately EMT [29-32]. These and 
other exogenous micro-environmental factors such as 
hypoxia and oxidative stress lead to a positive feedback 
loop further promoting EMT [33, 34] and increasing 
the inflammatory signals with consequences including 
immunosuppression mediated by T-regulatory cells 
and reduced efficacy of dendritic cells and cytotoxic 
T cells [35]. While at the molecular level, and usually 
in model systems, there are strong links between EMT 
and the TME, these are often difficult to study in human 
tumours. Localisation of immune cells has been reported 
as a predictor of progression [13-15] and the more recent 
inhibition of immune checkpoints suggest paracrine 
inhibition of cytotoxic T cells is critical for tumour 
progression [1]. Interestingly Djenidi et al. recently 
reported that the presence of CD8+ T cells expressing 
CD103 correlated with better overall survival in NSCLC, 
irrespective or localisation [16]. Induction of CD103 
expression requires MHC-peptide/TCR engagement in the 
presence of TGF-β1 and hence in situ by engaging tumour 
cells in the context of TGF-β1 rich microenvironment 
[36]. The acquisition of this resident memory T cell 
Table 1: Association of TME Markers with Overall Survival in Multivariate Analysis
No. of Patients No. of Deaths HR (95%CI) P Value
Total
CD8 62 30 1.091 (1.006-1.185) 0.036
CD68 62 30 1.007 (0.983-1.031) 0.580
FoxP3 62 30 0.955 (0.970-1.021) 0.728
Tumour Nest
CD8 62 30 0.917 (0.842-0.998) 0.044
CD68 62 30 0.981 (0.940-1.025) 0.396
FoxP3 62 30 1.024 (0.977-1.074) 0.319
Stromal
CD8 62 30 0.913 (0.842-0.991) 0.029
CD68 62 30 1.005 (0.982-1.029) 0.654
FoxP3 62 30 1.001 (0.977-1.026) 0.951
TN/STR
CD8 62 30 0.645 (0.427-0.974) 0.037
CD68 62 30 0.889 (0.745-1.061) 0.192
FoxP3 62 30 0.920 (0.823-1.028) 0.140
CAF Markers
Cav-1 62 30 0.635 (0.413-0.635) 0.038
Tn-C 62 30 2.309 (1.287-4.143) 0.005
EMT Markers
E-Cadherin 41 22 1.642 (0.436-6.183) 0.464
Vimentin 41 22 1.150 (0.180-7.329) 0.883
Combination
CD8 TN/STR & High Cav-1 & 
Low Tn-C
62 30 3.207 (1.907-5.392) <0.001
Bold type indicates significance p<0.05. TN/STR= tumour nest: stromal ratio.
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phenotype (T
RM
) also includes up-regulation of checkpoint 
proteins including PD-1, rationalising the efficacy of 
PD-1 inhibitor trials and supported by in vitro tumour cell 
killing by CD8+ CD103+ cells when under PD-1 blockade 
[16]. The main receptor for CD103 is E-cadherin, the 
down-regulation of which is a key event in EMT. Here, 
we show for the first time that a low level of tumour 
cell E-cadherin is associated with low levels of immune 
cells (CD8+ T cells, CD68+ macrophages or FoxP3+ 
T-regs) in the tumour nest. This may be explained if 
E-cadherin/CD103 interaction is required to retain the 
cells in the tumour nest, after the initial TCR-peptide/
MHC interaction in the presence of TGF-β1, in the case of 
CD8+ T cells. Subsequent migration to the stroma would 
potentially result in loss of CD103+ once TCR-peptide/
MHC interactions are lost and cells would potentially 
interact with Tn-C further leading to their inactivation. 
Therefore, low E-cadherin, low tumour nest CD8 and 
low total CD103+ T cells would be indicative of tumours 
progressing though EMT with lack of T-cell control all 
ultimately as a results of microenvironment driven factors 
including CAF-derived TGF-β and oxidative stress.
By simultaneously profiling the intertwined 
components of the TME, we have identified individual 
factors that predict overall survival, a connection 
between immune retention and E-cadherin and ultimately 
combinatorial risk factors which identify those with 
dramatically reduced overall survival.
MATERIALS AND METHODS
Patients
Fresh surgical material from tumour resections 
at Nottingham University Hospitals NHS Trust, were 
collected with informed patient consent and National 
Research Ethics Service (NRES) approval (NRES REC 
10/H0405/6) between March 2010 and April 2012. 
Samples were used in accordance with NRES approval 
(NRES REC 08/H0403/37). Patients were followed 
up to April 2015. Histological subtype and tumour 
stage were determined by pathologists at Nottingham 
University Hospitals NHS Trust according to Word Health 
Organisation criteria [37] and tumour, node, metastasis 
(TNM) stage criteria published by the International 
Association for the Study of Lung Cancer committee [38].
Immunohistochemistry
Serial 5μm thick sections of formalin-fixed 
and paraffin-embedded (FFPE) tissue were cut for 
immunohistochemical analysis by microtome and mounted 
on polylysine-coated slides. Following deparaffinisation 
and re-hydration antigen retrieval was performed by 
heating to 98°C in a temperature controlled microwave 
in retrieval buffer according to manufacturer’s instruction. 
Sections were then quenched, blocked in a 3% hydrogen 
peroxide solution for 10 mins, washed (H
2
0) blocked 
with streptavidin and then biotin (Vector Laboratories). 
Sections were subsequently washed in buffer, blocked 
in 5% rabbit serum and then incubated with the primary 
antibody or isotype and concentration matched negative 
control. After washing, sections were incubated with 
a secondary biotinylated rabbit anti-mouse antibody 
(DAKO), washed and incubated in avidin and then biotin 
complex (ABC) solutions according to manufacturer’s 
instructions (Vector Laboratories). Sections were 
washed incubated with 3,3’-diaminobenzidine (DAB) 
(DAKO), washed and counterstained with haematoxylin. 
Subsequently the sections were washed, dehydrated 
and cleared before mounting a coverslip with Distyrene 
Plasticizer Xylene (DPX).
Antibodies used in this study were: mouse anti-
human CD3 (DAKO, M7254, Clone F7.2.38) 7 μg/
ml, mouse anti-human CD8 (DAKO, M710301, 
Clone C8/144B) 3 μg/ml, mouse anti-human FOXP3 
(eBiosciences, 14-4777-82, clone 236A/E7) 2.5 μg/ml, 
mouse anti-human CD68 (DAKO, M0876, clone PG-M1) 
0.02 μg/ml, mouse anti-human vimentin (DAKO, M0725, 
clone V9) 4 μg/ml, mouse anti-human E-cadherin (DAKO, 
M3612, clone NCH38) 3 μg/ml, mouse anti-human 
caveolin-1 (BD Biosciences, 610407, Clone 2297) 0.5 μg/
ml and mouse anti-human tenascin-C (AbCam, Ab86182, 
Clone DB7) 5 μg/ml.
Scoring and image analysis
Immune cell infiltrate
A total of six images for each tissue section were 
obtained at 20x magnification (18.2 mm2 field of view) 
using a Leica DFC480 colour-inverted microscope; with 
three tumour nest (TN) hotspot and three stromal (STR) 
hotspot images taken. The hotspots were defined as a field 
of view with the most apparent accumulation of stained 
cells in either areas of tumour epithelia or stromal cells (as 
determined by tissue architecture). The stained cells were 
subsequently counted using ImageJ version 1.46r, “cell 
counter” plug-in and a TN and STR total was obtained 
for each image. The sum of the TN and STR cell numbers 
from all 6 images was determined to allow the total ratio 
(TN/STR) to be calculated for a given tissue section.
E-cadherin
On six fields of view E-cadherin was quantified 
using ImageScope software (Version 11.1.2.760) with 
‘Positive Pixel Count v9.1’ algorithm and thresholds set 
at high positive- 200, positive- 150, weak positive- 100. 
The algorithm generated an H-score using the formula: 
H-Score = (3 x percentage of high positive pixels) + (2 x 
percentage of medium positive pixels) + (1 x percentage 
of low positive pixels).
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Vimentin
Slides were visually scanned by two blinded 
operators for any vimentin staining in any tumour cells 
and presence of any vimentin in tumour was scored as 
positive.
Caveolin-1 and Tenascin-C
Sections were scored by three blinded assessors for 
the degree of stromal staining 0= 0-1%, 1= 2-10%, 2= 11-
50%, 3=>50%. Where scores from each assessor varied 
the majority (2 of 3 scorers) was recorded.
Statistical analysis
Kaplan-Meier survival analysis was performed in 
GraphPad Prism software (v6.04) and Log-rank (Mantel-
Cox) test P value reported. Where appropriate the Gehan-
Breslow-Wilcoxon test P value was reported which is 
weighted for early death. Where there were more than two 
groups log-ranks test for trend was also reported.
For multivariate Cox-regression analysis data was 
analysed in SPSS Statistics (v22, IBM) with gender, age, 
histological type and stage as covariates alongside data 
from immunohistochemical staining.
Analysis of correlation between E-cadherin H-score 
and CD8 TN/STR ratio was performed in GraphPad Prism 
software using Spearman’s non-parametric correlation. 
Difference in TIL TN/STR ratio or number of those 
patients with low E-cadherin H-Score and those with 
moderate or high E-cadherin was tested by Mann-Whitney 
unpaired non-parametric T-test (GraphPad Prism).
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